Abstract:2030 Background: Approximately 5% of advanced stage breast cancer (BC) will develop leptomeningeal disease, a rare form of metastasis in the meninges, a membrane surrounding the brain and spinal cord. The prognosis for BC-LMD is dismal and currently available treatments are ineffective. For example, intrathecal (IT) therapy such as trastuzumab, and proton cranial spinal radiotherapy have only showed modest success. Dendritic cells are a master regulator of the immune system and play a critical role in bridging the innate and adaptive immune response. Here, we used a novel preclinical model to administer MHC class II peptide-pulsed conventional Type 1 dendritic cells (cDC1s) intrathecally in mice that harbor either HER2+ or triple negative breast cancer (TBNC) LMD. Our murine BC-LMD murine data lead us to open a Phase 1 clinical trial of cDC1s in HER2+ and TNBC LMD (NCT05809752; in progress). Methods: Our lab developed a “murine Ommaya” which mimics the clinically used Ommaya reservoir and allows for repeated intrathecal (IT) injections of novel drugs at 3 – 7µl volume directly into the CSF. We next developed a pipeline for screening immunogenic MHC class II peptides from tumor-associated oncodrivers and using these targets to generate tumor-targeting cDC1s. We tested the resulting vaccines in a preclinical model that IT delivers peptide-pulsed cDC1 cell therapy directly into the BC-LMD microenvironment. Results: We tested the efficacy of treatment in HER2+ LMD and TNBC-LMD models and found effective responses; LMD mice that received IT cDC1 therapy exhibited reduced tumor burden and prolonged survival that was significantly better than systemic therapy. Approximately 70% of mice from HER2+ LMD and 30% from TNBC LMD demonstrated complete responses. This was CD4+ T cell dependent. Notably, cured mice also showed signs of resistance against LMD recurrence upon rechallenge. Subsequent single cell RNA-seq (scRNA-seq) analyses of the CSF showed a shift in the innate immune landscape found in untreated LMD to an adaptive immune landscape. In addition, we noted the elevated secretion of Th1 proinflammatory cytokines such as IFN-γ in the CSF. This was recapitulated in the CSF samples of patients enrolled in an on-going phase 1 trial, where early data showed IT cDC1 triggered a high concentration of several proinflammatory cytokines. Conclusions: Our preclinical data suggest IT cDC1 vaccine is effective against BC-LMD and prevents LMD recurrence. We are currently investigating the mechanism(s) by which IT cDC1-initiates the CD4 Th1 adaptive immune response against LMD. By employing an scRNA-seq approach, we hope to further determine the roles of different immune cells and their subtypes in the CSF to IT cDC1s in mice and in patients. A future approach includes testing IT cDC1 platform in LMD from other cancers (e.g. melanoma etc.).

Antitumor Immunity by a Dendritic Cell Vaccine Encoding Secondary Lymphoid Chemokine and Tumor Lysate on Murine Prostate Cancer

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

TGF-β insensitive dendritic cells: an efficient vaccine for murine prostate cancer

More Than Chemotaxis: A New Anti-Tumor DC Vaccine Modified by Raav2-Slc

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer

Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses

Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Dendritic Cells Transduced with a PSMA-encoding Adenovirus and Cocultured with Autologous Cytokine-Induced Lymphocytes Induce a Specific and Strong Immune Response Against Prostate Cancer Cells.

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Dendritic cell trafficking in tumor-bearing mice

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Recombinant adeno-associated virus encoding secondary lymphoid tissue chemokine(rAAV-SLC) efficiently infected mouse BMDC

DC Targeting DNA Vaccines Induce Protective and Therapeutic Antitumor Immunity in Mice.

Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.

Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets